4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Intramedullary primary spinal cord melanoma: illustrative case

      case-report
      , BS 1 , , MD, MSCI 2 , , MD 2 , , , BS 3 , , BS 1 , , MD 2 , , MD 2 , , MD, PhD 4 , , MD 4 , , MD 5 , , MD 6 , , MD, MBA 1 , , MD 1
      Journal of Neurosurgery: Case Lessons
      American Association of Neurological Surgeons
      primary spinal melanoma, intramedullary, spinal cord tumor, microsurgery, case report, CNS = central nervous system, CSF = cerebrospinal fluid, EMA = epithelial membrane antigen, GFAP = glial fibrillary acidic protein, GTR = gross-total resection, HMB = human melanoma black, ICI = immune checkpoint inhibitor, IPSM = intramedullary primary spinal melanoma, MART-1 = melanoma antigen recognized by T cell, MEP = motor evoked potential, MITF = microphthalmia-associated transcription factor, MRI = magnetic resonance imaging, PSM = primary spinal melanoma, RT = radiation therapy, SSEP = somatosensory evoked potential, STR = subtotal resection.

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          BACKGROUND

          Intramedullary primary spinal melanoma (IPSM) is a rare tumor, with limited reports on its clinical presentation, radiographic features, histopathological and genetic factors, diagnosis, and management.

          OBSERVATIONS

          A 49-year-old male presented with a 9-month history of intermittent, progressive left upper-extremity radiculopathy and left-sided numbness. Magnetic resonance imaging revealed an intramedullary tumor at the C6–T1 vertebral levels. Intraoperatively, upon opening the dura, the tumor was noted to be dark in appearance. Dorsal column mapping allowed for safe myelotomies above and below the tumor bulk, and a gross-total resection was achieved. The patient awoke with mild decreased lower-extremity sensation and proprioception but full motor strength. Surgical pathology was consistent with melanoma. Further workup ruled out the possibility of alternative primary neoplastic sites, and a diagnosis of IPSM was made. The patient was planned for radiation therapy (RT) and immune checkpoint inhibitor therapy in follow-up.

          LESSONS

          Fewer than 40 cases of IPSM have been described in the literature. While patients with IPSM present with progressive symptomology and unique imaging findings, surgical pathology is required for a diagnosis. The optimal treatment paradigm likely includes resection, RT, and/or systemic therapies. Molecular and genetic markers might enable more efficient diagnosis and optimize therapy for these patients.

          https://thejns.org/doi/10.3171/CASE24732

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          Frequent somatic mutations of GNAQ in uveal melanoma and blue nevi

          BRAF and NRAS are common targets for somatic mutations in benign and malignant neoplasms that arise from melanocytes situated in epithelial structures and lead to constitutive activation of the MAP-kinase pathway1, 2. However, BRAF and NRAS mutations are absent in a number of other melanocytic neoplasms in which the equivalent oncogenic events are currently unknown3. We report frequent somatic mutations in the heterotrimeric G protein alpha subunit, GNAQ, in blue nevi (83%) and ocular melanoma of the uvea (46%). The mutations occur exclusively in codon 209 in the ras-like domain and result in constitutive activation, turning GNAQ into a dominant acting oncogene. Our results demonstrate an alternative route to MAP-kinase activation in melanocytic neoplasia providing new opportunities for therapeutic intervention.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer

            Among more than 200 BAP1 -mutant families affected by the “BAP1 cancer syndrome,” nearly all individuals inheriting a BAP1 mutant allele developed one or more malignancies during their lifetime, mostly uveal and cutaneous melanoma, mesothelioma, and clear-cell renal cell carcinoma. These cancer types are also those that, when they occur sporadically, are more likely to carry somatic biallelic BAP1 mutations. Mechanistic studies revealed that the tumor suppressor function of BAP1 is linked to its dual activity in the nucleus, where it is implicated in a variety of processes including DNA repair and transcription, and in the cytoplasm, where it regulates cell death and mitochondrial metabolism. BAP1 activity in tumor suppression is cell type– and context-dependent. BAP1 has emerged as a critical tumor suppressor across multiple cancer types, predisposing to tumor development when mutated in the germline as well as somatically. Moreover, BAP1 has emerged as a key regulator of gene–environment interaction.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma.

              Uveal melanoma is a lethal cancer with a strong propensity to metastasize. Limited therapeutic options are available once the disease has disseminated. A strong predictor for metastasis is the loss of chromosome 3. Inactivating mutations in BAP1 encoding the BRCA1-associated protein 1 and located on chromosome 3p21.1, have been described in uveal melanoma and other types of cancer. In this study, we determined the prevalence of somatic BAP1 mutations and examined whether these mutations correlate with the functional expression of BAP1 in uveal melanoma tissue and with other clinical, histopathological and chromosomal parameters. We screened a cohort of 74 uveal melanomas for BAP1 mutations, using different deep sequencing methods. The frequency of BAP1 mutations in our study group was 47%. The expression of BAP1 protein was studied using immunohistochemistry. BAP1 staining was absent in 43% of the cases. BAP1 mutation status was strongly associated with BAP1 protein expression (P<0.001), loss of chromosome 3 (P<0.001), and other aggressive prognostic factors. Patients with a BAP1 mutation and absent BAP1 expression had an almost eightfold higher chance of developing metastases compared with those without these changes (P=0.002). We found a strong correlation between the immunohistochemical and sequencing data and therefore propose that, immunohistochemical screening for BAP1 should become routine in the histopathological work-up of uveal melanoma. Furthermore, our analysis indicates that loss of BAP1 may be particularly involved in the progression of uveal melanoma to an aggressive, metastatic phenotype.
                Bookmark

                Author and article information

                Journal
                J Neurosurg Case Lessons
                J Neurosurg Case Lessons
                J Neurosurg Case Lessons
                Journal of Neurosurgery: Case Lessons
                American Association of Neurological Surgeons
                2694-1902
                10 March 2025
                10 March 2025
                : 9
                : 10
                : CASE24732
                Affiliations
                [1 ]Zucker School of Medicine at Hofstra University/Northwell Health , Hempstead, New York
                [2 ]Department of Neurosurgery , Northwell Health, Manhasset, New York
                [3 ]SUNY Downstate College of Medicine , Brooklyn, New York
                [4 ]Department of Pathology , Northwell Health, Manhasset, New York
                [5 ]Department of Neurology , Zuckerberg Cancer Center, Northwell Health, New Hyde Park, New York
                [6 ]Department of Hematology and Medical Oncology , Northwell Health, Manhasset, New York
                Author notes
                Correspondence Daniel Schneider: North Shore University Hospital, Northwell Health, Manhasset, NY. dschneider5@ 123456northwell.edu .

                INCLUDE WHEN CITING Published March 10, 2025; DOI: 10.3171/CASE24732.

                Disclosures Dr. Carvajal reported personal fees from Ideaya Biosciences, Immunocore, Mural Oncology, TriSalus Life Sciences, and Replimune outside the submitted work. Dr. Sciubba reported personal fees from DePuy Synthes, Medtronic, Stryker, Baxter, NuVasive, and Pacira Pharmaceuticals, Inc. outside the submitted work.

                Author information
                http://orcid.org/0000-0002-5617-9009
                http://orcid.org/0009-0008-3330-455X
                http://orcid.org/0000-0003-4088-6232
                http://orcid.org/0000-0001-7604-434X
                Article
                CASE24732
                10.3171/CASE24732
                11894282
                40063999
                9ac38e95-10d2-470f-816c-9ef7ab5b7a67
                © 2025 the authors

                CC BY-NC-ND 4.0 ( http://creativecommons.org/licenses/by-nc-nd/4.0/)

                History
                : 21 October 2024
                : 22 November 2024
                Categories
                Oncology, Oncology
                Spine, Spine
                Cervical, Cervical
                Tumor, Tumor
                Case Lesson

                primary spinal melanoma,intramedullary,spinal cord tumor,microsurgery,case report,cns = central nervous system,csf = cerebrospinal fluid,ema = epithelial membrane antigen,gfap = glial fibrillary acidic protein,gtr = gross-total resection,hmb = human melanoma black,ici = immune checkpoint inhibitor,ipsm = intramedullary primary spinal melanoma,mart-1 = melanoma antigen recognized by t cell,mep = motor evoked potential,mitf = microphthalmia-associated transcription factor,mri = magnetic resonance imaging,psm = primary spinal melanoma,rt = radiation therapy,ssep = somatosensory evoked potential,str = subtotal resection.

                Comments

                Comment on this article